none
Conditions
Interventions
Group 1: CYP3A4 wild type and CYP3A5 wild type (CCAA):None
Group 2: CYP3A4 heterozygous mutation and CYP3A5 wild type (CTAA):None
Group 3: CYP3A4 homozygous mutation and CYP3A5 wild type (TTAA):None
Group 4: CYP3A4 wild type and CYP3A5 Heterozygous mutant (CCAG):None
Group 5: CYP3A4 heterozygous mutation and CYP3A5 heterozygous mutant (CTAG):None
Group 6: CYP3A4 homozygous mutation and CYP3A5 heterozygous mutant (CTAG):None
Group 7: CYP3A4 wild type and CYP3A5 homozygous mutant (CCGG):None
Group 8: CYP3A4 heterozygous mutation and CYP3A5 homozygous mutant (CTGG):None
Group 9: CYP3A4 homozygous mutation and CYP3A5 homozygous mutant (TTGG):None
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Male or female aged 18-60 years; 2. ASA (American Society of Anesthesiologists) grade I-III, liver function child-Pugh grade A; 3. BMI 18-28; 4. Laparoscopic gastrointestinal or urinary surgeries, thoracoscopic esophageal and lung surgeries, or neurosurgical surgeries are planned to be performed under general anesthesia, and the anesthesia surgery can be administered stably and continuously for more than 120 minutes.
Exclusion criteria
Exclusion criteria: 1. Preoperative combination with severe cardiopulmonary vascular disease, diabetes mellitus, severe liver and/or renal dysfunction; 2. Preoperative history of chronic pain and psychiatric history; 3. Preoperative hypovolemia or hypotension; 4. History of fentanyl drug allergy and drug abuse; 5. Alcoholism, drug abuse or long-term use of painkillers; 6. Pregnant and lactating women; 7. Have taken drugs or foods that can inhibit or induce the expression of CYP3A enzyme within 1 week before surgery; 8. Those who have used monoammonia oxidase inhibitors within 2 weeks before surgery; 9. Other conditions that the investigator considers inappropriate to participate in clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in blood drug concentration before and after stopping continuous infusion of sufentanil for 2 hours;Pharmacokinetic parameters of sufentanil after continuous infusion for 2 hours and discontinuation; | — |
Secondary
| Measure | Time frame |
|---|---|
| CYP3A4 genotype;CYP3A5 genotype; | — |
Countries
China
Contacts
Public ContactJianteng Gu
The First Affiliated Hospital (Southwest Hospital) of Army Medical University
Outcome results
None listed